Gamida Cell develops NAM-modified allogeneic cell therapies intended to treat hematologic malignancies. Its lead product, Omisirge (omidubicel-onlv), is an FDA-approved nicotinamide-modified allogeneic hematopoietic progenitor cell therapy. The company also advances GDA-201, an intrinsic natural killer (NK) cell therapy candidate. Gamida leverages proprietary nicotinamide technology to enhance and expand cells for potentially curative treatments. Recent leadership changes (CEO Dr. Joe Wiley, CFO Rory Nealon, CCO Sheila Frame) accompany a new ownership structure and capital infusion to support commercialization. The company now operates as a wholly owned subsidiary of Ayrmid Limited (a UK entity) and is pursuing broader access to Omisirge while continuing R&D and manufacturing efforts. Gamida Cell is a clinical-stage developer of cellular and immune therapies focused on treatments for cancer and orphan genetic diseases. Its lead product, NiCord, is an FDA Breakthrough Designated, stand-alone graft derived from a single umbilical cord blood unit expanded using the company’s proprietary NAM technology. NiCord is being developed to facilitate bone marrow transplantation for patients without a rapidly available fully matched donor and the company is currently enrolling an international, multi-center Phase 3 registration study. Gamida Cell’s pipeline also includes CordIn for rare genetic diseases and NK cells as a treatment for cancer, and the company is developing products to address conditions such as sickle cell disease, thalassemia, aplastic anemia, and other genetic and refractory autoimmune diseases. The company plans to expand in-house manufacturing capacity and increase its presence in the US to support late-stage development and commercialization. Gamida Cell develops cellular and immune therapies targeting cancer and orphan genetic diseases. Its core programs include NiCord for hematological malignancies, CordIn for sickle cell disease and thalassemia, and NK cell therapies for cancer. The company is conducting a Phase 3 registration study for NiCord and clinical trials for CordIn and NK cells. It received up to $4.4M in non-dilutive grant funding from the Israel Innovation Authority to support ongoing R&D and these clinical programs. The pipeline also targets bone marrow failure syndromes, genetic metabolic diseases and refractory autoimmune diseases. Gamida Cell is led by Dr. Yael Margolin and counts Novartis, Elbit Imaging, Clal Biotechnology Industries, Israel Healthcare Venture, Teva, Denali Ventures and Auriga Ventures among its shareholders. Gamida Cell develops cellular and immune therapies targeting cancer and orphan genetic diseases. Its pipeline includes programs for cancer, genetic hematological diseases such as sickle cell disease and thalassemia, genetic metabolic diseases, and refractory autoimmune diseases. NiCord is an experimental product for high‑risk hematological malignancies derived from a single cord blood unit expanded and enriched with stem cells and immune modulatory cells using the company’s proprietary NAM technology. The company plans to initiate a Phase III clinical trial of NiCord in mid‑2016. Novartis is a significant financial backer and has committed additional equity funding to advance clinical programs. Gamida Cell’s shareholders also include Elbit Imaging, Clal Biotechnology Industries, Israel Healthcare Venture, Teva Pharmaceutical Industries, Denali Ventures and Auriga Ventures. Gamida Cell is a Jerusalem-based provider of stem cell expansion technologies and therapeutic products. Its lead investigational product, NiCord, is derived from a single cord blood unit and expanded and enriched with stem cells using the company’s proprietary NAM technology. NiCord is being evaluated as the sole stem cell source in a Phase I/II study for hematological malignancies including leukemia and lymphoma. The company is led by president and CEO Dr. Yael Margolin. In connection with development plans for NiCord, Gamida Cell received a $35M strategic investment from Novartis Pharma. The deal includes equity and an acquisition option tied to development milestones, providing potential near-term funding and a path to commercialization.

Total raised

$124M

Funding rounds

6

Latest round

Equity

Latest activity

Jun 2024